Larimar Therapeutics, Inc.
LRMR
$3.44
-$0.06-1.71%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -74.32% | -105.54% | -103.79% | -71.05% | -111.26% |
| Total Depreciation and Amortization | 0.00% | 10.06% | 5.59% | 0.62% | 4.15% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 102.93% | 49.96% | 41.67% | -18.03% | -52.19% |
| Change in Net Operating Assets | 455.24% | 662.70% | 1,012.97% | -66.96% | 110.47% |
| Cash from Operations | -51.08% | -59.98% | -65.54% | -114.90% | -139.24% |
| Capital Expenditure | 92.55% | 82.33% | 46.00% | 29.45% | -243.90% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 5,813.72% | 218.30% | 180.38% | 144.36% | 98.42% |
| Cash from Investing | 4,560.62% | 217.48% | 179.75% | 144.09% | 97.98% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 262,630.30% | -59.75% | -59.72% | -99.96% | -99.96% |
| Repurchase of Common Stock | 39.82% | 39.82% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 64,727.24% | -59.79% | -59.64% | -99.96% | -100.17% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 274.73% | 809.94% | 1,587.14% | 79.91% | -6,314.01% |